Jan 11, 2023
Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference
Jan 04, 2023
Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis
Displaying 21 - 22 of 22
Oct 11, 2023 at 3:30 PM PDT
Helen Sabzevari, PhD, President and CEO, Precigen, to provide a company presentation on Wednesday, October 11 at 3:30 PM PT at the Cell & Gene Meeting on the Mesa conference taking place from October 10 to 12 in Carlsbad, California.
Oct 24, 2023 at 5:00 PM - 7:00 PM CEST
Dr. Scott M. Norberg, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, will present an abstract titled, "Significant clinical benefit and enhanced T-cell responses with repeated administration of PRGN-2012, a novel gorilla adenoviral vector based immunotherapy, in adult patients with severe Recurrent Respiratory Papillomatosis.